The warning comes from the Medicines and Healthcare products Regulatory Agency (MHRA) following careful ongoing review of the risks. The drug may also reduce the effectiveness of oral contraception. Women taking modafinil should take effective measures to prevent pregnancy and discuss their contraception options with their healthcare professional.
Modafinil is used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant. Now, a large registry study involving over two million pregnant women in Sweden and Norway shows that there is no such association. The study, which is published in JAMA, was conducted by researchers at Sweden's Karolinska Institutet and the Norwegian Institute of Public Health.
Mired in pay-for-delay lawsuits over its narcolepsy drug Provigil, Teva’s Cephalon is looking to clear the field. A class-action settlement in Pennsylvania could help ease investors’ minds.
Even with a lack of peer-reviewed evidence, the number of centers advertising stem cell therapies for osteoarthritis (OA) of the knee are increasing in the United States. These centers claim an 80 percent success rate, according to research presented this week at the 2018 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS). Of the 65 centers that provided pricing information to treat OA of the knee, the cost ranged from $1,150 to $12,000, with an average of $5,000 per injection
Zydus Pharm’s Generic Modafinil Receives Tentative Approval In US
Appco Pharma’s Generic Modafinil Receives Approval In US
Sun Pharma Posts Surprise Loss On Antitrust Litigation
European regulators believe that Teva and Cephalon breached antitrust rules with an agreement that effectively delayed the entry of generic competition to the latter’s blockbuster sleep disorder drug modafinil.
The European Commission has informed pharmaceutical company Teva of its preliminary view that an agreement concluded with Cephalon was in breach of EU antitrust rules. Under the agreement, Teva committed not to market a cheaper generic version of Cephalon's drug for sleep disorders, modafinil.